Novartis AG
Close on Nov 2, 2026Market cap $308.20BP/E 22.6Yield –
Novartis Patients Reached (million people — ex-Sandoz) by Year
Patients Reached (million people — ex-Sandoz) (M)
Novartis Patients Reached (million people — ex-Sandoz): 304M in FY2025, up 2.7% from a year earlier.
Where the FY2025 figure comes from
“| Patients reached (millions) | 304 | 296 | ∆ |”
Source: Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗
Restated on a consistent basis for continuing operations (excluding Sandoz) for FY2022–FY2025.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Patients Reached (million people — ex-Sandoz) (M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 304 | +2.7% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2024 | Dec 31, 2024 | 296 | +4.2% | Novartis Official IR / Sustainability Report — novartis-esg-data-summary-2025.pdf ↗ |
| FY2023 | Dec 31, 2023 | 284 | +6.4% | Novartis Form 6-K (0001370368-25-000008) ↗ |
| FY2022 | Dec 31, 2022 | 267 | – | Novartis Form 6-K (0001370368-25-000008) ↗ |
Breakdown
What makes up patients Reached (million people — ex-Sandoz)
- Access Approaches (million people)30 · FY2025
- LMICs Strategic Innovative Therapies (people)2,161,186 · FY2025
- Global Health Flagship Programs — Malaria, Leprosy, Chagas, SCD (people)25,880,574 · FY2025
- Malaria & NTDs R&D Investment142 · FY2025
- Share of New Product Launches with Global Access Strategy (%)100.0% · FY2025
- Number of Countries with Novartis Products Available118 · FY2025
Cite this data
StockData. (2026). Novartis Patients Reached (million people — ex-Sandoz) (M), annual FY2022–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/access-patients-reached-total-m
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.